Loading provider…
Loading provider…
Hematology & Oncology Physician in Scottsdale, AZ
NPI: 1114929114Primary Employer
Honorhealth Ambulatory
honorhealth.com
HQ Phone
Get MD Michael's Phone Numberphone_androidMobile
Get MD Michael's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAZ State Medical License
AZ State Medical License
2000 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Jacobs School of Medicine and Biomedical Sciences
medicine.buffalo.edu
Medical School
Until 1985
Memorial Sloan Kettering Cancer Center
Fellowship • Hematology and Medical Oncology
1988 - 1991
University of Chicago
Residency • Internal Medicine
1985 - 1988
Sophie Davis School for Biomedical Education at CCNY
BS • Biomedical Science
1979 - 1983
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 57 | 111 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 49 | 59 |
Authors: Gwendolyn Cody, Wael Harb, Carol Aghajanian, Vicky Makker, Rachel Grisham
Journal: Clin Cancer Res
Publication Date: 2018-05-29
Authors: Antonio Jimeno, Joaquina Baranda, Alain Mita, Oladapo Yeku, Wade Iams, Monica Mita
Journal: Invest New Drugs
Publication Date: 2023-03-03
Real-Time Template-Assisted Manipulation of Nanoparticles in a Multilayer Nanofluidic Chip
Authors: Chen, H Matthew, Pang, Lin, Gordon, Michael S, Fainman, Yeshaiahu
Journal: Small
Publication Date: 2011-08-15
Lead Sponsor: Revolution Medicines, Inc.
Collaborators: Sanofi
Intervention / Treatment: DRUG: Cobimetinib, DRUG: RMC-4630, DRUG: Drug: Osimertinib
Lead Sponsor: Agenus Inc.
Intervention / Treatment: DRUG: Botensilimab, DRUG: Balstilimab
Lead Sponsor: Celldex Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: pembrolizumab, DRUG: Chemotherapy, DRUG: CDX-301, DRUG: CDX-1140